Skip to content

Study · Animal study (in vivo) · rat · 1996

12 results

Bone-selective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model.

Lane NE, Kimmel DB, Nilsson MH, Cohen FE, Newton S, Nissenson RA, Strewler GJ

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 May 1996Cited by 37 (Europe PMC)

PMID9157776 (opens in a new tab)DOI10.1002/jbmr.5650110509 (opens in a new tab)PepBankPUB-09157776
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, native hPTH did not significantly increase cancellous bone volume.

    In plain wordsIn ovariectomized rats, native hPTH did not significantly increase spongy bone volume compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCancellous bone volume
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    4, 40, or 400 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    None of the compounds significantly increased the cancellous bone volume.
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, trabecular number did not change with hPTH treatment.

    In plain wordsIn ovariectomized rats, hPTH did not change trabecular number compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTrabecular number
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    4, 40, or 400 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    Trabecular number declined after OVX and did not change with hPTH treatment.
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, medium-dose native hPTH increased trabecular thickness.

    In plain wordsIn ovariectomized rats, medium-dose native hPTH increased trabecular thickness compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular thickness at medium dose
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    In contrast, the trabecular thickness declined after OVX but was higher after treatment with 40 mu g/kg of BW/day or 400 mu g/kg of BW/day of hPTH(1-34).
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, high-dose native hPTH increased trabecular thickness.

    In plain wordsIn ovariectomized rats, high-dose native hPTH increased trabecular thickness compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTrabecular thickness at high dose
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    In contrast, the trabecular thickness declined after OVX but was higher after treatment with 40 mu g/kg of BW/day or 400 mu g/kg of BW/day of hPTH(1-34).
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, native hPTH produced dose-related increases in mineralizing surface.

    In plain wordsIn ovariectomized rats, native hPTH increased mineralizing bone surface with increasing dose compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMineralizing surface
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    4, 40, or 400 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    All three peptides produced marked dose-related increases in the mineralizing surface and bone formation rates, but the two analogs were less potent than hPTH(1-34).
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, native hPTH produced dose-related increases in bone formation rates.

    In plain wordsIn ovariectomized rats, native hPTH increased bone formation with increasing dose compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone formation rate
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    4, 40, or 400 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    All three peptides produced marked dose-related increases in the mineralizing surface and bone formation rates, but the two analogs were less potent than hPTH(1-34).
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, native hPTH produced significant dose-related increases in serum osteocalcin.

    In plain wordsIn ovariectomized rats, native hPTH increased blood osteocalcin with increasing dose compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum osteocalcin
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    4, 40, or 400 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    Likewise, all peptides produced significant dose-related increases in the serum osteocalcin level.
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, medium-dose native hPTH decreased osteoclast surface.

    In plain wordsIn ovariectomized rats, medium-dose native hPTH decreased bone surface occupied by bone-resorbing cells compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseOsteoclast surface at medium dose
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    40 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    The osteoclast surface was not affected by OVX but was decreased with medium and high doses of hPTH(1-34).
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, high-dose native hPTH decreased osteoclast surface.

    In plain wordsIn ovariectomized rats, high-dose native hPTH decreased bone surface occupied by bone-resorbing cells compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseOsteoclast surface at high dose
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    The osteoclast surface was not affected by OVX but was decreased with medium and high doses of hPTH(1-34).
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, native hPTH did not significantly affect pyridinoline cross-link excretion.

    In plain wordsIn ovariectomized rats, native hPTH did not significantly affect pyridinoline cross-link excretion compared with vehicle.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePyridinoline cross-link excretion
    Study

    Ratn: not reported in source

    Ovariectomized Sprague-Dawley rats
    Comparator
    Vehicle
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    4, 40, or 400 mu g/kg BW/day · injectionAs given in this study (Rat).

    Source sentences

    Summary
    Pyridinoline cross-link excretion was not significantly affected by treatment with hPTH(1-34) but responded with a dose-dependent decrease to treatment with [His3]hPTH(1-34).
    3 context sentences
    Summary · context
    Histomorphometry of the proximal tibia metaphysis and biochemical markers of bone turnover (osteocalcin and pyridinoline cross-links) were the primary endpoints.
    Summary · context
    On day 56 post-OVX, five sham-operated and five pre-PTH treatment OVX animals were sacrificed, and the remaining animals were randomized into 10 groups of six animals each.
    Summary · context
    All other animals were injected with one of the hPTH analogs or hPTH(1-34) at 0, 4, 40, or 400 mu g/kg of body weight (BW)/day and were killed on day 84.
  11. 11LabIn vitro (cells)Activity measurement

    In renal OK cells, native hPTH produced greater maximal cAMP activation than either substituted analog.

    In plain wordsIn cells, native hPTH produced greater maximum cAMP activation than either substituted analog.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRelative cAMP activation in OK cells
    Study

    n: not reported in source

    Renal OK cell line
    Comparator
    His-substituted and Leu-substituted analogs
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the renal cell line OK, maximal cyclic adenosine monophosphate (cAMP) activation by [His(3)]hPTH(134) was 50%, and maximal cAMP activation by [Leu(3)]hPTH(1-34) was 20% of that produced by hPTH(1-34).
  12. 12LabIn vitro (cells)Activity measurement

    In bone-derived systems, native hPTH had greater potency than both substituted analogs.

    In plain wordsIn cells, native hPTH had greater potency than both substituted analogs.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRelative potency in bone-derived cells
    Study

    n: not reported in source

    UMR-106 rat osteosarcoma cells and other bone-derived systems
    Comparator
    His-substituted and Leu-substituted analogs
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both analogs were full agonists in UMR-106 rat osteosarcoma cells and other bone-derived systems, but both had reduced potency compared with hPTh(1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.